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Role of HDL Cholesterol and Estimates of HDL Particle
Composition in Future Development of Type 2
Diabetes in the General Population: The PREVEND
Study
Ali Abbasi, Eva Corpeleijn, Ron T. Gansevoort, Rijk O. B. Gans, Hans L. Hillege,
Ronald P. Stolk, Gerjan Navis, Stephan J. L. Bakker, and Robin P. F. Dullaart
Department of Epidemiology (A.A., E.C., H.L.H., R.P.S.) and Department of Internal Medicine
(A.A., R.T.G., R.O.B.G., G.N., S.J.L.B., R.P.F.D.), University Medical Center Groningen, University of
Groningen, Groningen 9700 RB, The Netherlands
Background and Aims:High-density lipoproteins (HDLs) may directly stimulate -cell function and
glucose metabolism. We determined the relationships of fasting high-density lipoprotein choles-
terol (HDL-C), plasma apolipoprotein (apo) A-I and apoA-II, and HDL-C–to–apoA-I and HDL-C–to–
apoA-II ratios, as estimates of HDL particle composition, with incident type 2 diabetes mellitus.
Methods: A prospective study was carried out in the Prevention of Renal and Vascular End-Stage
Disease (PREVEND) cohort after exclusion of subjects with diabetes at baseline (n  6820; age,
28–75 years). The association of HDL-related variables with incident type 2 diabetes was deter-
mined by multivariate logistic regression analyses.
Results: After a median follow-up of 7.7 years, 394 incident cases of type 2 diabetes mellitus
were ascertained (5.8%). After adjustment for age, sex, family history of diabetes, body mass
index, hypertension, alcohol, and smoking, odd ratios (ORs) for diabetes were 0.55 (95%
confidence interval [CI], 0.47–0.64; P  .001), 0.81 (0.71–0.93; P  .002), 0.02 (0.01–0.06; P 
.001), and 0.03 (0.01–0.060; P  .001) per 1-SD increase in HDL-C and apoA-I and in the HDL-
C–to–apoA-I and the HDL-C–to–apoA-II ratios, respectively. In contrast, apoA-II was not related
to incident diabetes (OR 1.02; 95%CI, 0.90–1.16; P0.71). The relationships of HDL-C and the
ratios of HDL-C to apoA-I and HDL-C to apoA-II remained significant after further adjustment
for baseline glucose and triglycerides (ORHDL  0.74 [95% CI, 0.61–0.88], ORHDL/APO A-I  0.14
[0.04–0.44], and ORHDL/APOA-II  0.12 [0.04–0.36]; all P  .001).
Conclusions: Higher HDL-C, as well as higher HDL-C–to–apoA-I and HDL-C–to–apoA-II ratios are
strongly and independently related to a lower risk of future type 2 diabetes. (J Clin Endocrinol
Metab 98: E1352–E1359, 2013)
The epidemic of type 2 diabetes mellitus poses a majorpublic health concern worldwide (1, 2). Much atten-
tion is currently being paid to the development and vali-
dation of diabetes prediction models to optimize guide-
lines for diabetes prevention (3–5). Many of the proposed
diabetes risk scores take account of metabolic syndrome
components, including high-density lipoprotein (HDL)
cholesterol (HDL-C) (4, 5). Indeed, lower levels ofHDL-C
confer a higher incidence of type 2 diabetes in various
ethnic populations and age groups (6–12), analogous to
the cardiovascular protection attributed to HDL (13, 14).
In search of better predictors, mechanisms that play a role
in the early pathophysiology of type 2 diabetes, indepen-
dent of established risk factors, are of interest.
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The inverse relationship of HDL-C with diabetes de-
velopment is not surprising in the context of coexisting
obesity anddisturbances in lipoproteinmetabolism in sub-
jects at high risk for diabetes (15–17). Notably, evidence
has accumulated recently that HDL may also be directly
involved in the pathogenesis of type 2 diabetes mellitus by
virtue of its ability to enhance pancreatic -cell function
and glucose uptake in skeletal muscle (18–20). Further-
more, defects in the functional properties of HDL have
been shown to result in increased susceptibility of pancre-
atic -cells to oxidative stress, apoptosis, islet inflamma-
tion, and cholesterol accumulation (20). HDL is able to
restore oxidized low-density lipoprotein–induced impair-
ment of insulin processing in vitro, whereas free apolipo-
protein (apo)A-I andalso reconstitutedHDLparticles and
native HDL of which apo A-I is the most abundant apo-
lipoprotein constituent, have been shown to stimulate in-
sulin secretion by enhancing cholesterol efflux out of
-cells (21–23). In agreement with a contributory role of
HDL functionality on the maintenance of insulin secre-
tion, both the antioxidative capacity of HDL and the abil-
ity of plasma to stimulate cholesterol efflux from cultured
fibroblasts have been found to be independent determi-
nants of -cell function in well-controlled type 2 diabetes
mellitus (24). Of further relevance, apoA-I stimulates the
AMP-activated protein kinase pathway in myocytes in
vitro (25). Reconstituted HDL infusion also stimulates
this pathway in skeletal muscle from subjects with type 2
diabetes in vivo (21). HDL could, therefore, lower plasma
glucose not only by stimulation of insulin secretion but
also by stimulation of glucose uptake via an insulin-inde-
pendent mechanism (18, 21).
Despite the current focus on the allegedly beneficial
effects ofHDLonglucosehomeostasis, it is still notknown
whether the major apolipoproteins of HDL, apoA-I and
apoA-II, are independently related to incident type 2 di-
abetes mellitus in the general population. The same is true
for HDL particle characteristics. Importantly, apoA-I and
apoA-II exert specific effects on HDL functional proper-
ties (16, 26), are protein constituents of distinct HDL sub-
fractions, ie, LpA-I and LpA-I:A-II particles (27, 28), and
may have dissimilar potentials in identifying early pro-
cesses in the development of cardiovascular disease (29,
30) and possibly also in development of type 2 diabetes.
For these reasons, it is clinically relevant to discern
whether diabetes development is dependent not only on
HDL-C but also on plasma levels of apoA-I and apoA-II.
The present study was initiated to determine the
strengthof associationsof incident type2diabetesmellitus
with HDL-C, plasma apoA-I and apoA-II, and HDL par-
ticle composition, as estimated by the ratios of HDL-C to
apoA-I andHDL-C to apoA-II. To this end,we performed
a prospective study in the population-based Prevention of
Renal and Cardiovascular End-Stage Disease (PREVEND)
cohort.
Materials and Methods
Study population and design
The PREVEND studywas approved by the local medical eth-
ics committee, University Medical Center Groningen, and was
performedaccording to theprinciplesoutlined in theDeclaration
of Helsinki. All participants gave written informed consent. De-
tails on study design, recruitment, and procedures have been
reported elsewhere (31).
The study population is based on the PREVEND study, a
Dutch cohort drawn from the general population (age ranged
between 28 and 75 years) of the city of Groningen, The Neth-
erlands. After exclusion of patients with insulin-treated diabetes
mellitus and pregnant women, all subjects with a urinary albu-
min concentration (UAC) of10 mg/L (n 7768) were invited
to participate, of whom 6000 accepted. In addition, 3394 ran-
domly selected subjects with a UACof10mg/Lwere invited to
participate, of whom 2592 accepted. These 8592 subjects par-
ticipated in the baseline screening and constitute the actual PRE-
VEND cohort. From this baseline cohort, we first excluded 336
individuals with prevalent cases of diabetes. These patients were
defined by either a self-report of physician diagnosis or screening
at first visits (1996–1997). Other exclusions were for 285 sub-
jects with no follow-up data or who could not be linked to the
pharmacy registry and 807 individuals with nonfasting blood
sampling or those using lipid-lowering agents (n 344), leaving
6820 participants who were free of baseline diabetes for our
cohort analysis.
Clinical and laboratory measurements
During 3 rounds of screening from 1997 to 1998 (baseline
examination) until January 1, 2007 (third examination), the par-
ticipants underwent 2 outpatient visits to assess medical history,
anthropometry, and cardiovascular and metabolic risk factors,
and they had to collect 2 24-hour urine samples. We collected
information on use of medications via data from pharmacy reg-
istries of all community pharmacies in the city ofGroningen (32).
Hypertension was defined by self-reported physician diagnosis,
use of antihypertensive medication, or blood pressure140/90
mmHg. Total cholesterol and plasma glucose weremeasured by
a dry chemistry method (Eastman Kodak, Rochester, New
York). HDL-Cwasmeasured by a homogeneous method (direct
HDL, Aeroset System; Abbott Laboratories, Abbott Park, Illi-
nois). Serum apoA-I and apoA-II were determined by nephelom-
etry, applying commercially available reagents ( apoA-I test kit,
code no. OUED and apoA-II test kit, code no. OQBA) for Dade
Behring nephelometer II systems (Dade Behring, Marburg, Ger-
many). Fasting insulin was measured with an AxSYM autoana-
lyzer (Abbott Diagnostics, Amstelveen, The Netherlands). Insu-
lin resistance was assessed based on the homeostasis model
assessment for insulin resistance (HOMA-IR), which is calcu-
lated by the following formula: [glucose (millimoles per liter)
insulin (milliunits per liter]/22.5 (33). Triglycerides were mea-
sured enzymatically. UAC was determined by nephelometry
with a threshold of 2.3 mg/L and intra- and interassay coeffi-
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cients of variation of less than 2.2% and less than 2.6%, respec-
tively (Dade Behring). Urinary albumin excretion (UAE) is given
as themeanof the 224-hour urine collections.All the technicians
were blinded to the participants’ characteristics.
Outcome definition
Incident cases of type 2 diabetes mellitus were ascertained as
described previously (4, 34). In brief, type 2 diabetes was ascer-
tained if one or more of the following criteria were met: (1)
fasting plasma glucose 7.0 mmol/L (126 mg/dL); (2) random
sample plasma glucose 11.1 mmol/L (200 mg/dL); (3) self-
report of a physician diagnosis; and (4) initiation of glucose-
lowering medication use retrieved from a central pharmacy reg-
istry (33, 34).We included cases from3months after the baseline
screening visits.
Statistical analysis
Continuous data were compared by using Student t tests or
Mann-Whitney U tests, where applicable. We used 2 tests for
the comparisonof categorical variablesbetween individualswith
andwithout incident type 2diabetes. Logistic regression analysis
was used to examine the associations of HDL variables, ie,
HDL-C, apoA-I, apoA-II, and HDL-C–to–apoA-I and HDL-–
to–apoA-II ratios with the risk of developing type 2 diabetes.
Odds ratios (ORs) for type 2 diabetes were calculated per SD
change for each HDL variable with 95% confidence intervals
(CIs). Inmodel 1, basic adjustmentwas for age and sex. Inmodel
2, we further adjusted for body mass index (BMI) or waist cir-
cumference. In model 3, we additionally adjusted for family his-
tory of diabetes, hypertension, alcohol use, and smoking. In
models 4 and 5, we further adjusted for fasting glucose and
triglycerides plus fasting glucose, respectively. In addition, we
also performed analysis in which we adjusted for HOMA-IR
as covariate. In model A, we adjusted for those variables in
model 3 and for HOMA-IR. In model B, we further adjusted
for triglycerides. For HOMA-IR and triglycerides, logarith-
mic transformation with base 2 (log2) was used.
Given the expected strong negative relationship of HDL-C
with triglycerides, a potential confounder in the associations of
interest, we also calculated ORs (95% CI) of HDL variables
across each tertile of triglycerides. To this end, the associations
of diabetes incidencewithHDL-C, theHDL-C–to–apoA-I ratio,
and theHDL-C–to–apoA-II ratiowere ascertainedwith the low-
est HDL variable being used as the reference category in each
triglyceride tertile. Subsequently,wecalculated interaction terms
forHDL-C sex in eachmodel andperformed sex-specific anal-
ysis. In view of the enrichment of the PREVEND participants
with microalbuminuric subjects (31), we accounted for 24-hour
UAE at baseline as another potential confounding factor in the
secondary analysis. Next, we repeated regression models by us-
ing aweightedmethod to compensate for baseline enrichment of
the PREVEND participants with high UAC (ie, 10 mg/L or
greater). Weight change might confound the associations of
HDL-C, the HDL-C–to–apoA-I ratio, and the HDL-C–to–
apoA-II ratio with risk of diabetes. Therefore, we calculated ab-
solute and percentage weight change in 4757 participants who
underwent follow-up screening at the third examination. As a
secondary analysis, we added absolute weight change to a mul-
tivariable model including age, sex, family history of diabetes,
hypertension, glucose, triglycerides, andHDL-Cor the ratios.As
another secondary analysis,we addedpercentageweight change,
calculated as (weightexamination-third  weightexamination-first)/
(weightexamination-first) 100 to this multivariate model. For
most baseline variables,1%was missing, whereas this was up
to 8% for self-reported variables such as family history of dia-
betes mellitus. A single imputation and predictive mean match-
ing method was applied for missing data. Two-sided P values
.05 were considered statistically significant. All the statistical
analyses were performed using IBM SPSS Statistics 19 and R
(version 2.13.1 for Windows; http://cran.r-project.org/).
Results
During median (interquartile range [IQR]) follow-up for
7.7 (7.4–8.0) years, 394 individuals (5.8%) developed
new-onset type 2 diabetes mellitus. Baseline clinical and
laboratory characteristics of the total cohort and a com-
parison of individuals who developed new-onset type 2
diabetes vs individuals who remained free of diabetes are
shown inTable1. Individualswith incident type2diabetes
were older,more likely tobemale,more obese,more likely
to have a family history of diabetes, and more likely to
have hypertension than those who did not develop diabe-
tes (P .001). Levels of fasting glucose, insulin, HOMA-
IR, total cholesterol, triglycerides, and 24-hour UAEwere
significantly higher in individuals who developed new-
onset type 2 diabetes vs those without incident diabetes.
Concentrations of HDL-C, apoA-I, and apoA-II and the
ratios of HDL-C to apoA-I and HDL-C to apoA-II were
significantly lower in individuals who developed new-on-
set type 2 diabetes mellitus than in subjects who did not
develop diabetes (P  .001 for all).
HDL variables and risk of type 2 diabetes
ORs (95% CI) for incident type 2 diabetes per 1-SD
increase in HDL-C, apoA-I, and apoA-II and the ratios of
HDL-C to apoA-I and HDL-C to apoA-II are shown in
Table 2. In age- and sex-adjusted analysis, allHDL-related
variables were significantly associated with risk of inci-
dent type 2 diabetes (P  .001), except for apoA-II (P 
.77) (model 1). Further adjustment forBMI, family history
of diabetes, hypertension, alcohol use, and smoking did
notmaterially change these associations (models 2 and 3).
After further adjustment for baseline fasting glucose and
triglycerides, HDL-C, as well as the HDL-C–to–apoA-I
and the HDL-C–to–apoA-II ratios, remained indepen-
dently associated with risk of incident diabetes (models 4
and 5). In the fully adjusted models, the strongest effect
sizewas observed for theHDL-C to apoA-I andHDL-C to
apoA-II ratios (ORs of 0.14 and 0.12, respectively; P 
.001 for each). Furthermore, the directions and the strengths
of the relationships were similar in analyses in which we ad-
justedforwaistcircumferenceinsteadofBMI(seeSupplemental
Table 1 published onThe Endocrine Society’s JournalsOnline
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websiteathttp://jcem.endojournals.org.).AsshowninFigure1,
we also observed that the risk of diabetes of HDL-C and the
ratiosofHDL-CtoapoA-IandHDL-CtoapoA-IIdidnotdiffer
across triglyceride tertiles (P .10 for interactions).
ORs for incident type 2 diabetes mellitus per a 1-SD
increase in HDL-C, apoA-I, apoA-II, HDL-C–to–apoA-I
ratio, and HDL-C–to–apoA-II ratio with HOMA-IR in-
corporated in model 4 instead of plasma glucose are
shown in Table 3. In multivariable adjusted analysis now
controlling for insulin resistance, triglycerides, and other
clinical diabetes risk factors, all results remained essen-
tially similar.
Secondary analyses
In secondary analyses, we additionally accounted for
24-hour UAE as an additional covariate (other included
confounders are as inmodel5) (Table2).Weobserved that
HDL-C and ratios of HDL-C to apoA-I and apoA-II were
Table 1. Baseline Clinical and Laboratory Characteristics of Participants
Total Noncases
Incident Cases of
Type 2 Diabetes P Value
No. of participants (%) 6820 (100) 6426 (94.2) 394 (5.8)
Male, n (%) 3247 (47.6) 3021 (47.0) 226 (57.4) .001
Age, y 48.8  12.5 48.3  12.4 56.3  10.8 .001
Family history of diabetes, n (%) 1339 (19.6) 1196 (18.6) 143 (36.3) .001
Smoking, n (%)
Current 2296 (33.7) 2162 (33.6) 134 (34.0)
Former 2463 (36.1) 2308 (35.9) 155 (39.3) .22
Never 2061 (30.2) 1956 (30.4) 105 (26.6)
Alcohol use, n (%)
4 drinks per day 347 (5.1) 326 (5.1) 21 (5.3)
1–3 drinks per day 1334 (19.6) 1259 (19.6) 75 (19.0)
2–7 drinks per week 2315 (33.9) 2205 (34.3) 110 (27.9) .07
1–4 drinks per month 1105 (16.2) 1034 (16.1) 71 (18.0)
Almost never 1719 (25.2) 1602 (24.9) 117 (29.7)
Systolic blood pressure, mm Hg 123.7  19.3 122.9  19.0 135.4  20.5 .001
Diastolic blood pressure, mm Hg 71.5  9.7 71.3  9.6 76.2  9.5 .001
Hypertension, n (%) 1790 (26.2) 1593 (24.8) 197 (50.0) .001
BMI, kg/m2 26.0  4.2 25.7  4.0 29.5  4.8 .001
Waist circumference, cm 87.8  12.9 87.2  12.7 98.7  12.3 .001
Glucose, mmol/L 4.7  0.6 4.7  0.6 5.6  0.7 .001
IFG, n (%)a 689 (10.1) 467 (7.3) 222 (56.3) .001
Insulin, mU/L 7.7 (5.4–11.3) 7.5 (5.4–10.9) 8.6 (12.8–19.8) .001
HOMA-IR 1.60 (1.08–2.46) 1.55 (1.06–2.33) 3.17 (2.08–5.19) .001
Total cholesterol, mmol/L 5.65  1.12 5.63  1.12 6.08  1.12 .001
HDL-C, mmol/L 1.34  0.40 1.35  0.40 1.11  0.29 .001
Triglycerides, mmol/L 1.12 (0.82–1.62) 1.10 (0.81–1.57) 1.63 (1.21–2.38) .001
apoA-I, g/L 1.40  0.27 1.40  0.28 1.32  0.24 .001
apoA-II, g/L 0.34  .06 0.34  0.06 0.33  0.06 .001
HDL-C–to–apoA-I ratio 0.96  0.20 0.96  0.21 0.84  0.16 .001
HDL-C–to–apoA-II ratio 3.96  1.24 4.00  1.25 3.33  0.83 .001
UAE, mg/24 h 9.2 (6.2–16.4) 9.0 (6.2–15.7) 15.1 (8.1–36.5) .001
Data are means  SD or median (IQR).
a IFG, impaired fasting glucose (fasting glucose of 6.1–6.9 mmol/L [110–125 mg/dL]).
Table 2. Relationships of HDL Variables With the Risk of Developing Type 2 Diabetes Mellitus
HDL Variables












HDL-C 0.44 (0.38–0.51) .001 0.54 (0.46–0.63) .001 0.55 (0.47–0.64) .001 0.63 (0.53–0.74) .001 0.74 (0.61–0.88) .001
apoA-I 0.72 (0.64–0.82) .001 0.80 (0.71–0.92) .001 0.81 (0.71–0.93) .002 0.89 (0.77–1.03) .11 0.95 (0.82–1.10) .50
apoA-II 0.98 (0.87–1.10) .77 1.03 (0.91–1.16) .63 1.02 (0.90–1.16) .71 1.07 (0.92–1.21) .43 1.01 (0.88–1.16) .83
HDL-C–to–
apoA-I ratio
0.005 (0.002–0.013) .001 0.02 (0.007–0.050) .001 0.02 (0.01–0.06) .001 0.05 (0.02–0.13) .001 0.14 (0.04–0.44) .001
HDL-C–to–
apoA-II ratio
0.006 (0.002–0.015) .001 0.02 (0.007–0.044) .001 0.03 (0.01–0.06) .001 0.05 (0.02–0.12) .001 0.12 (0.04–0.36) .001
Model 1: adjusted for age and sex. Model 2: model 1  BMI. Model 3: model 2  family history of diabetes, hypertension, alcohol use, and
smoking. Model 4: model 3  glucose. Model 5: model 4  triglycerides.
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strongly associated with risk of incident type 2 diabetes
after multivariable adjustment for 24-hour UAE, fasting
glucose, and triglycerides plus other clinical diabetes risk
factors (Supplemental Table 2). To account for baseline
enrichment of the PREVEND cohort with microalbumin-
uric subjects, we subsequently repeated the analysis in
model 5 when we weighted for individuals with mean
UAC 10 mg/L. This complex design analysis hardly af-
fected the ORs in model 5 (Supplemental Table 3). In ad-
dition, the associations of HDL-C and the ratios of
HDL-C to apolipoproteins with the risk of incident type 2
diabetes were not modified by sex (P  .10 for interac-
tions). In sex-stratified analyses, the multivariable-ad-
justed ORs (adjusted for baseline fasting glucose, triglyc-
erides and other clinical risk factors) per 1-SD increase of
HDL-Cwere 0.70 (0.55–0.91, P .007) and 0.74 (0.57–
0.96, P  .025) in men and women, respectively. In sub-
sequent secondary analyses limited to 4757 participants
who underwent follow-up screening at examination 3,
median (IQR) weight change and percentage weight
change were 2.0 (1.0 to 5.0) kg and 2.3% (1.6% to
6.8%), respectively. Addition of absolute weight change
to model 5 (Table 2) did not materially affect the associ-
ations of HDL-C and the ratios of HDL-C to apo A-I and
apo A-II with the risk of incident type 2 diabetes; the re-
spective ORs were 0.68 (0.54–0.85, P  .001), 0.09
(0.02–0.39, P  .001), and 0.05 (0.01–0.22, P  .001).
The same was true for addition of percentage weight
change to model 5, resulting in respective ORs of 0.68
(0.54–0.85), 0.09 (0.02–0.39), and 0.05 (0.01–0.22).
Discussion
This prospective study in apredominantlyCaucasianpop-
ulation shows that the age- and sex-adjusted relationship
of incident type 2 diabetes mellitus with HDL-C is at least
in part independent of other metabolic syndrome compo-
nents, including (central) obesity, hypertension, fasting
plasma glucose, and triglycerides, as well as of a positive
family history of diabetes. Higher HDL-C levels were also
related to a lower risk of diabetes after further adjustment
for alcohol consumption and smoking, important envi-
ronmental factors that govern HDL-C. More strikingly,
incident diabetes was related to plasma apoA-I levels as
well, in marked contrast with the lack of any independent
relationship of diabetes development with plasma apoA-
II. As judged from the respective ORs, the relationship of
incident diabetes with apoA-I was weaker than that with
HDL-C. As a consequence, we observed robust inverse
relationships of incident diabetes with the HDL-C–to–
apoA-I and the HDL-C–to–apoA-II ratio. Of note, the
particularly low ORs are partly a consequence of the fact
that small changes in ratios can reflect relatively large
changes in HDL-C or apolipoprotein differences. Taken
together, the present data are in keeping with the hypoth-
Figure 1. Risk of developing type 2 diabetes mellitus according to
tertiles of HDL-C (A), the HDL-C–to–apoA-I ratio (B) and the HDL-C–
to–apoA-II ratio (panel C) stratified by triglyceride tertiles. The ORs
(95% CI) were calculated by logistic regression models adjusted for
age and sex. The individuals in the first HDL tertile were considered as
the reference category (P  .10 for interactions).
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esis that HDL particles that contain apoA-I rather than
apoA-II may influence diabetes development. This result
raises the possibility that compositional characteristics of
specific HDL particles besides the well established com-
ponents of themetabolic syndromemay be involved in the
pathogenesis of type 2 diabetes mellitus.
Besides increasing age and a positive family history of
diabetes, (central) obesity, hypertension, andhigher initial
plasma glucose are relevant components of the early
pathophysiology of type 2 diabetesmellitus (3–5). Thus, it
is necessary to take account of these cardiometabolic risk
factors to determine the strength of the relationships of
incident diabeteswithHDL-related variables. Previous re-
ports have already demonstrated that lower HDL-C re-
lates to increased diabetes risk after adjustment for several
metabolic syndrome components in predominantly mid-
dle-aged Caucasian men (9, 10), in Korean subjects (12),
and even in native American children and adolescents
(11). In some early surveys, the impact of HDL-C on di-
abetes incidencewas found tobe confined towomen (7,8).
In the PREVEND cohort, we did not find an interaction
between sex and HDL-C on incident diabetes, and the
point estimatesofHDL-Cfordiabetes riskwere similar for
men andwomen separately. In view of the strong negative
relationships of HDL-C and HDL particle size with
plasma triglycerides (16, 27, 28, 35, 36), it is also relevant
that the impact of the HDL-C–to–apoA-I and the HDL-
C–to–apoA-II ratios on diabetes development was not ap-
preciablymodifiedbyplasma triglyceride levels.Although
not unequivocally established, the impact of apoA-II on
HDLremodeling, aswell as on the functional properties of
HDL, such as the ability to promote cell-derived choles-
terol efflux, is likely to be distinct and less pronounced
than the multifaceted actions of apoA-I, which are gener-
ally considered to be antiatherogenic (26–28, 37). In this
context, it is plausible to propose that the lack of associ-
ation of apoA-II compared with apoA-I with incident di-
abetes would translate into a differentiated role of these
apolipoproteins in their ability to protect against diabetes
development. Of further interest, the lowest ORs for in-
cident diabeteswere found for theHDL-C–to–apoA-I and
the HDL-C–to–apoA-II ratios. Higher ratios of HDL-C
comparedwith thoseof themajor apolipoproteinsofHDL
provide estimates of more cholesterol loaded and, hence,
larger HDL particles (16, 27–29, 38). Therefore, the
strong negative relationship of these ratios with diabetes
development suggests that larger HDL particles may par-
ticularly relate to lower diabetes incidence. In keeping
with this supposition and in line with the lack of relation-
ship of diabetes developmentwith apoA-II, HDLparticles
that contain both apoA-I and apoA-II, ie, LpA-I:A-II par-
ticles, are smaller than LpA-I particles, which contain
apoA-I only (28). Obviously, the possible diabetes-pro-
tective impact of variousHDL subfractions including pre-
-HDL and the contribution of specific HDL-associated
proteins, such as the antioxidative enzymes, paraoxonase
I and lipoprotein-associated phospholipase A2 (26, 27,
39), needs to be more precisely defined in future human
studies. Nevertheless, this large-scale prospective study
based on observational data strongly supports previous in
vitro and in vivo evidence regarding a potential mecha-
nistic link between HDL particle properties and future
development of type 2 diabetes. The present findings also
provide a rationale to test the importance of HDL size
characteristics on incident diabetes mellitus.
Several methodological aspects and limitations of our
study need to be considered. The PREVEND cohort is
enriched with microalbuminuric subjects (31). In this co-
hort, microalbuminuria was shown to predict incident di-
abetes independently of metabolic syndrome components
(40). Nonetheless, the incidence of type 2 diabetes among
PREVENDparticipants during amedian follow-up of 7.7
years with January 1, 2007, as census date, ascertained
according to 1997 American Diabetes Association crite-
ria, as well as by self-reported physician diagnosis of type
2 diabetes or the use of oral glucose-lowering drugs,
roughly agrees with current projections of diabetes prev-
alence in other established market economies (1, 2, 4, 5).
Clearly, it is relevant to take account ofmicroalbuminuria
upon establishing the relationship of diabetes develop-
Table 3. Relationships of HDL Variables With the Risk of Developing Type 2 Diabetes Mellitus After Adjustment for
HOMA-IR and Other Clinical Factors
HDL Variable
OR (95% CI) per 1-SD Increase
Model A P Value Model B P Value
HDL-C 0.66 (0.56–0.77) .001 0.76 (0.64–0.89) .001
apoA-I 0.88 (0.77–1.01) .08 0.93 (0.82–1.07) .33
apoA-II 1.02 (0.90–1.16) .71 1.01 (0.88–1.14) .91
HDL-C–to–apoA-I ratio 0.07 (0.02–0.19) .001 0.16 (0.05–0.51) .002
HDL-C–to–apoA-II ratio 0.07 (0.03–0.18) .001 0.14 (0.05–0.41) .001
Model A: adjusted for age, sex, BMI, smoking, alcohol use, family history of diabetes, hypertension, and HOMA-IR. Model B: model A 
triglycerides.
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ment with HDL. Additional adjustment for 24-hour UAE
did not materially change the ORs of any HDL-related
variables for incident diabetes. Furthermore, a secondary
analysis weighted for the enrichment of the PREVEND
cohort with higher UACs (31) revealed comparable dia-
betes risk estimates for the HDL-C–to–apoA-I and the
HDL-C–to–apoA-II ratio. Hence, a clinically important
bias in the interpretation of the current results attributable
to overrepresentation of microalbuminuric subjects con-
sequent to the focus of PREVEND on renal disease is un-
likely but cannot be excluded. Although early use of met-
formin is currently recommended for prevention of
diabetes in individuals with prediabetes, this approach
was not recommended by national guidelines within the
time frame of our cohort study. Therefore, overdiagnosis
of diabetes due to early metformin use is unlikely. In the
PREVENDstudy, hemoglobinA1cwas notmeasured, and
oral glucose tolerance testswerenotperformed. If elevated
levels of hemoglobin A1c or results of oral glucose toler-
ance tests would serve as diagnostic criteria in addition to
elevated fasting glucose (41), the absence of these tests in
our study would result in false-negative cases of diabetes,
with an underestimation of its incidence. The presence of
such false-negative cases couldmask an otherwise present
association if the underlying association is marginal. If,
however, associations are demonstrated, as in our study,
the possibility of false-negative cases implies that the as-
sociation could be stronger than actually observed.More-
over,weonly investigatedHDL-C, apoA-I, and apoA-II as
estimates of theHDLparticle composition, andwedid not
directly measure HDL size. Finally, we had no data on
physical activity that might have influenced the extent to
which HDL-related parameters associate with diabetes
development.
In conclusion, our study demonstrates for the first time
that new-onset type 2 diabetes mellitus is related not only
to lowerHDL-Cbut also is strongly related to lowerHDL-
C–to–apoA-I and HDL-C–to-apoA-II ratios, as estimates
of HDL particle characteristics. We hypothesize that spe-
cific HDL particles may independently affect pathophys-
iological pathways involved diabetes development.
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